In the BioHarmony Drug Report Database
Crisaborole
Eucrisa, Staquis (crisaborole) is a small molecule pharmaceutical. Crisaborole was first approved as Eucrisa on 2016-12-14. It is used to treat atopic dermatitis in the USA. It has been approved in Europe to treat atopic dermatitis. It is known to target cAMP-specific 3′,5′-cyclic phosphodiesterase 4B, high affinity cAMP-specific 3′,5′-cyclic phosphodiesterase 7A, and calcium/calmodulin-dependent 3′,5′-cyclic nucleotide phosphodiesterase 1A. Eucrisa’s patents are valid until 2030-01-20 (FDA).
Trade Name
|
Staquis |
|---|---|
Common Name
|
crisaborole |
ChEMBL ID
|
CHEMBL484785 |
Indication
|
atopic dermatitis |
Drug Class
|
Boroles, boron compounds |
Image (chem structure or protein)